Cardiopulmonary Stress Testing Systems Market Size by Product, Type, Application, End-User, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2034
Overview
The Cardiopulmonary Stress Testing Systems Market was valued at USD 4.69 Bn in 2025, and the total revenue of the Cardiopulmonary Stress Testing Systems Market is expected to grow at a CAGR of 4.5% from 2026 to 2034, reaching nearly USD 6.97 Bn by 2034.
Cardiopulmonary Stress Testing Systems Market Overview:
Cardiopulmonary Stress Testing Systems allow a clinician to determine whether a person's heart and lungs are functioning properly during activity. The amount of oxygen utilised while riding a bike, walking, or running on a treadmill is measured.
Cardiopulmonary Stress Testing Systems Market Growth and Share Analysis
To know about the Research Methodology :- Request Free Sample Report
Cardiopulmonary Stress Testing Systems Market Dynamics:
The rising prevalence of cardiovascular diseases and pulmonary disorders are major driving the market growth.
A rise in the global prevalence of many cardiovascular indications, such as atrial fibrillation, demanding the examination of cardiopulmonary function, is one of the key causes contributing to the growth. In addition, rising rates of lifestyle diseases, as well as heart and lung illnesses, are driving the cardiopulmonary stress testing market. Heart failures, ischemic heart disease, shortness of breath, and pulmonary problems are all evaluated and detected by the cardiopulmonary test.
One of the market's main drivers is the growing geriatric population. According to the United Nations, older people will account for more than 25% of the population in Europe and Northern America by 2050, 20% in Oceania, 17% in Asia, Latin America and the Caribbean, and 6% in Africa.
The existence of prominent manufacturers who are spending extensively on technical innovations to deliver superior care to CVD patients is boosting the market's growth. During the forecast period, a growing geriatric population pool will assist this. The relaxation offered by governing bodies in order to aid heart patients suffering from COVID-19 is also expected to boost the market growth. An increase in the number of product launches combined with an increase in the number of cardiac specialty centres will provide enormous growth prospects.
The report has profiled eighteen key players in the market from different regions. However, the report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for a future hot spot in APAC region.
Cardiopulmonary Stress Testing Systems Market Segment Analysis:
Based on Product, the Exercise Testing System segment is expected to hold a dominant market share during the forecast period. Because of the precision and less operating time of these devices, Exercise Testing Systems has the highest share of the market. Cardiopulmonary exercise testing (CPET) assesses integrative exercise responses involving the pulmonary, circulatory, haematopoietic, cognitive, and skeletal muscle systems that aren't effectively reflected by individual organ system function measurements.
Furthermore, the rising preference of physicians and patients for these devices due to their cost-effectiveness and diverse applications contributes to the rise in acceptance of these systems, which fuels the market's growth.
During the projection period, however, the stress ECG device is establishing its dominance in the global cardiac stress testing systems market, owing to a rising geriatric population with decreasing functional capability. Schiller AG is a market leader in cardiopulmonary stress testing services worldwide.
The company's product pipeline and technology for patient assessment via stress testing have been continuously improved. The CARDIOVIT AT-200 EXCELLENCE ERGOSPIRO is a device that can perform both pulmonary function tests (PFTs) and metabolic tests with diagnostic quality-12 or 16-lead exercise ECG, conveniently and reliably.
Based on Application, the cardiopulmonary stress testing systems market is segmented into cardiac applications, pulmonary applications and research & sports medicine. The Cardiac Applications segment held the largest share of the Cardiopulmonary Stress Testing Systems Market. Cardiac stress testing was widely used to assess heart function, diagnose coronary artery disease, and monitor patients with cardiovascular conditions. Hospitals and diagnostic centers heavily rely on cardiopulmonary systems to evaluate exercise tolerance and cardiac performance. The growing prevalence of heart disease and increased awareness about preventive cardiac care contributed to this segment’s dominance.
Cardiopulmonary Stress Testing Systems Market Recent Development:
| Date | Company | Development | Impact |
|---|---|---|---|
| 27 March 2025 | GE HealthCare | GE HealthCare unveiled the latest version of its CASE (Cardiac Assessment System for Stress Testing) platform, powered by CardioSoft technology, at the 2025 ACC Session. | The system enhances diagnostic accuracy by providing on-demand access to high-quality ECG data and streamlining cardiac stress workflow integration. |
| 16 November 2025 | Kauvery Hospital | Kauvery Hospital launched its specialized Kauvery Metabolic Wellness Centre featuring advanced metabolic carts for cardiorespiratory diagnostic assessments. | The deployment expands clinical access to precise cardiopulmonary stress evaluation and metabolic diagnostics for chronic disease management. |
| 19 November 2025 | Hexoskin | Hexoskin obtained U.S. FDA 510(k) clearance for the Hexoskin Medical System, a continuous ambulatory ECG and respiratory monitoring smart garment. | This clearance enables long-term real-world cardiopulmonary stress monitoring and non-invasive diagnostics in remote patient care and clinical trials. |
| 25 March 2026 | GE HealthCare | GE HealthCare showcased the U.S. commercial launch of its ReadyFix fleet management solution integrated with MAC VU360 resting ECG workstations at ACC 2026. | The solution improves operational efficiency through real-time diagnostics and remote software deployment across cardiac diagnostics fleets. |
Cardiopulmonary Stress Testing Systems Market Regional Insights:
North America is expected to dominate the global market throughout the forecast period.
Throughout the forecasted period, North America is likely to dominate the global cardiopulmonary stress testing (CPST) systems market. The CPST's dominance is owing to an increase in the occurrence of cardiovascular and pulmonary illnesses in the United States, such as arrhythmia, heart failures, ischemic heart disease, dyspnea, and heart valve imbalance, which drives up demand for the test.
According to a report published by the Journal of the American Medical Association in 2020, around 93.3 million persons over the age of 20 in the United States were obese, which is the leading cause of cardiac disorders, which is expected to drive market growth over the forecast period.
The report also helps in understanding the Global market dynamics, structure by analyzing the market segments and project the Global market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global market make the report investor’s guide.
Cardiopulmonary Stress Testing Systems Market Scope:Inquire before buying
| Global Cardiopulmonary Stress Testing Systems Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 4.69 Bn. |
| Forecast Period 2026 to 2034 CAGR: | 4.5% | Market Size in 2034: | USD 6.97 Bn. |
| Segments Covered: | by Product | Exercise Testing (CPET) Systems Stress ECG Systems Pulse Oximeters Single-Photon Emission Computed Tomography (SPECT) Others |
|
| by Type | Treadmill-Based Stress Testing Cycle Ergometer Testing Pharmacological Stress Testing |
||
| by Application | Cardiac Applications Pulmonary Applications Research & Sports Medicine |
||
| by End-User | Hospitals Specialty Clinics / Cardiology Clinics Diagnostic Centers Ambulatory Surgical Centers Others |
||
Cardiopulmonary Stress Testing Systems Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Cardiopulmonary Stress Testing Systems Market, Key Players:
1. Thermo Fisher Scientific Ltd.
2. Philips Healthcare
3. Care Medical Ltd.
4. Cosmed Medical and Cardiac Science Corporation
5. GE Healthcare
6. Cardinal Health
7. CareFusion Corporation (BD)
8. Spacelabs Healthcare (OSI Systems, Inc.)
9. MGC Diagnostic Corporation
10. Nihon Kohden Corporation
11. Schiller AG
12. SunTech Medical, Inc.
13. Welch Allyn
14. Hill-rom Holdings Inc
15. OSI Systems Inc
16. Masimo
17. Halma plc
18. Vyaire Medical Inc.
Frequently Asked Questions:
1. Which region has the largest share in the Global Cardiopulmonary Stress Testing Systems Market?
Ans: The North America region held the highest share in 2025.
2. What is the growth rate of the Global Cardiopulmonary Stress Testing Systems Market?
Ans: The Global Cardiopulmonary Stress Testing Systems Market is growing at a CAGR of 4.5% during the forecasting period 2026-2034.
3. What is the scope of the Global Market report?
Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. What was the Global Cardiopulmonary Stress Testing Systems Market size in 2025?
Ans: The Global Cardiopulmonary Stress Testing Systems market was valued at USD 4.69 Bn. In 2025.
5. What is the study period of this market?
Ans: The Global Market is studied from 2020 to 2034.